NewsRoom Articles - Page 9 of 115 - CanadianCannabisWire

MondayMay 22, 2023 9:45 am

Lexaria Bioscience Corp. (NASDAQ: LEXX) Completes Dosing in Human Oral Nicotine Study, Hopes to Facilitate More Satisfying Experience with DehydraTECH(TM)-Processed Oral Nicotine

Lexaria recently reported that dosing of the targeted 36 volunteers in its human clinical oral nicotine study, NIC-H22-1, had been completed The company hopes to demonstrate that its DehydraTECH(TM)-processed nicotine absorbs more quickly and more efficiently into the human bloodstream than leading oral nicotine brands Through previous animal testing, Lexaria showed that DehydraTECH-nicotine was up to 10x to 20x faster in delivering comparable levels of nicotine and delivered up to 6-fold higher levels of nicotine into blood plasma than concentration-matched controls If the findings from the human study replicate a similarly improved performance, Lexaria believes this could facilitate a more…

FridayMay 19, 2023 9:00 am

Lexaria Bioscience Corp. (NASDAQ: LEXX) Announces Pivotal Milestones Concerning DehydraTECH(TM) Technology, Including IND Application Plans

Lexaria's patented DehydraTECH(TM) technology enhances drug bioavailability, making it useful for a wide range of product formats, including pharmaceuticals, neutraceuticals, consumer packaged goods, and over-the-counter pills, capsules, tablets, and oral suspensions The company is currently exploring the potential benefits of DehydraTECH related to several molecules including, purified nicotine, CBD, antiviral drugs, human hormones, and PDE5 inhibitors Lexaria recently announced the completion of its diabetes animal study DIAB-A22-1 with at least three positive outcomes using DehydraTECH-CBD California-based InClin, Inc. has been awarded the contract for clinical research organization services for the expected upcoming FDA-registered, U.S. Phase 1b IND hypertension study, HYPER-H23-1…

TuesdayMay 16, 2023 9:45 am

Lift Toronto 2023 Cannabis Conference & Expo Promises to Energize, Inspire, Educate, and Motivate Audiences from Across the Cannabis Ecosystem

In October 2018, Canada became the first developed country to legalize recreational cannabis for adult use (https://cnw.fm/CnFvC). Aimed at curbing the illicit trade of the drug and launching a new source of economic growth, this move is playing a significant role in the economy. For instance, Deloitte’s study, which considered the direct, indirect, and induced economic activities, estimated that the industry had contributed US$43.5 billion to Canada’s economy between legalization and 2021 (https://cnw.fm/2CPiB). And as the country counts down to the fifth anniversary this October, the figure is expected to be higher, making the upcoming Lift Toronto 2023 Cannabis Conference…

TuesdayMay 16, 2023 9:00 am

Lexaria Bioscience Corp. (NASDAQ: LEXX) Kicks Off FDA IND Filing Process with Granted CRO Contract to California-Based InClin, Inc.

Lexaria just awarded InClin, Inc. the contract for CRO services, in a move that lines up with the company’s upcoming FDA-registered, U.S. Phase 1b IND hypertension study, HYPER-H23-1 InClin will manage the study in the form of clinical site evaluation and selection, project management, personnel, site training, and more Patient dosing is set to kick off as soon as possible once the expected FDA IND filing and review is completed, which Lexaria hopes will be done this summer HYPER-H23-1 will be Lexaria’s most ambitious study yet, and upon its completion, it will move the company closer to FDA approval of…

FridayMay 12, 2023 9:45 am

Lift Toronto 2023 Cannabis Conference & Expo Connects Brands, Investors, Growers & Consumers from Across the Cannabis Industry

Cannabis industry growers, processors, manufacturers, brands, budtenders, retailers, educators, advocates, regulators, consumers, investors, and more, are invited to attend the Lift Toronto 2023 Cannabis Conference & Expo to be held June 1-3, 2023, at the Metro Toronto Convention Centre. The three-day event will begin on Thursday, June 1, with the Lift Cannabis Business Conference (“LCBC”), an all-business strategy forum focused on generating meaningful change and sustainable growth within the Canadian cannabis industry. The conference will focus on the drivers of forward momentum, overcoming systemic challenges, and advancing innovative business and regulatory solutions. The LCBC sessions will include highlights such as…

ThursdayMay 11, 2023 9:45 am

BizCann Expo: An Elite Business & Networking Event for All Things Cannabis

BizCann Expo, a must-attend event for anyone working in the cannabis space, will be held in the city of Medellín, Columbia, May 20-21, 2023, a beautiful location surrounded by the spectacular Andes mountains. Colombia’s location an1d promising regulatory environment make it a rich location for the cannabis industry, with Medellin and nearby regions guiding its growth. BizCann is the leading event in South and Latin America driving education, entrepreneurship, and innovation in all facets of the cannabis industry. Whether you’re a recognized canna-entrepreneur, or you are looking to join this exhilarating industry, BizCann Expo has all the resources you’ll need…

MondayMay 08, 2023 9:00 am

Lexaria Bioscience Corp. (NASDAQ: LEXX) Announces Four New Patents Added to the Company’s Growing Patent Portfolio

Lexaria has received notifications of four new patents either awarded or allowed After the awarding of these patents, Lexaria's total patent portfolio will have grown to 32 granted patents worldwide The new granted patent in Japan is under Patent Family #3: Stable Ready-to-Drink Beverage Compositions Comprising Lipophilic Active Agents The new granted Australian patent is under Patent Family #18: Compositions and Methods for Enhanced Delivery of Antiviral Agents The new allowed Canadian patent is under Patent Family #8: Compositions Infused with Nicotine Compounds and Methods of Use Thereof The new allowed US patent is under Patent Family #21: Compositions and…

WednesdayMay 03, 2023 9:00 am

Lexaria Bioscience Corp. (NASDAQ: LEXX), Featured in Recent Research Report by Zacks SCR

Zacks recently released a research report covering Lexaria Bioscience, a global innovator in drug delivery platforms The report discusses the company’s ongoing research and development (“R&D”) programs, forecasting penetration into global markets for hypertension, oral nicotine delivery, and antiviral product categories Lexaria is targeting conditions with significant market potential, including hypertension, diabetes, dementia, and seizures These programs position the company for entry into collaborative opportunities to support further growth and provide growth capital Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms, featured in a recently released research report from Zacks Small-Cap Research (“SCR”) (https://cnw.fm/R891E). The report considers…

FridayApr 28, 2023 9:45 am

Lexaria Bioscience Corp.’s (NASDAQ: LEXX) Successful DIAB-A22-1 Diabetes Study Indicates Just One of Several Potential Applications for DehydraTECH(TM) Drug Delivery Platform Technology

Lexaria recently completed its diabetes animal model study, DIAB-A22-1, an ambitious study that explored the potential of its patented DehydraTECH(TM)-processed cannabidiol (“CBD”) for the treatment of diabetes The study showed at least three primary positive outcomes, including weight loss and improved triglyceride and cholesterol levels, with lower doses of DehydraTECH-CBD achieving the most optimum outcome The success of this study inches Lexaria closer to capitalizing on the potential of the diabetes drug market, estimated at $63.1 billion in 2021 It also points to the technology’s effectiveness, particularly following the success of the company’s most ambitious clinical study, HYPER-H21-4, demonstrating the…

MondayApr 17, 2023 9:45 am

Lexaria Bioscience Corp. (NASDAQ: LEXX) Eyes the Licensed Use of its DehydraTECH(TM) Technology to Complement its Royalty Earnings and Realize Revenue in Advance of Royalties

Chris Bunka, Lexaria’s CEO, has reiterated the company’s commitment to creating value for its shareholders with the licensed use of its patented DehydraTECH(TM) technology Mr. Bunka has noted that Lexaria is already in discussions with interested parties in Europe and North America, a move that presents a critical fiscal opportunity for the company He has emphasized how profitable new licensing agreements could be for the company, presenting additional avenues for Lexaria to generate revenue and create value for its shareholders As the company continues to make a transition toward a more commercial focus in 2023, Bunka notes that licensing will…

News and Publishing Service for Cannabis Related, Canadian Companies

Contact us: 512.354.7000